News

According to the Alnylam, the new study performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics and AlCana Technologies, described a

The Phase 2 trial enrolled 140 patients who have been randomised to either orBec or placebo at a 2:1 ratio. The primary endpoint of this trial is the

Derma Sciences has hired Maeve Kelly as managing director for EMEA (Europe, Middle East, Africa regions). Ms Kelly will report directly to Barry Wolfenson, executive vice president of

For the first quarter of 2010, Ranbaxy Laboratories has posted a EBITDA of $298m, compared to a loss of $201m for the prior year period. Profit after tax

Biotage recently entered into collaboration with the German instrument company MultiSynTech (privately owned by Udo Treffer) and professor Jensen to develop the Biotage Syro Wave automated peptide synthesiser

Aesica supplies active pharmaceutical ingredients, formulations and custom synthesis products to pharmaceutical and biotechnology industries. It was formed in 2004 after a management buy-out of the former BASF

According to the FDA, Cefepime should be used only to treat or prevent bacterial infections in hospitals and healthcare centers. And especially, the infections that are proven or

Achillion Pharmaceuticals said that the subjects in the third cohort of HCV-infected patients received doses of 200mg twice-daily (randomised to 6 active drug, 3 placebo) for five days.

Vical said that the Phase 2 trial was a single-arm, open-label study in which 127 chemo-refractory or chemo-intolerant patients subjects were treated with high-dose Allovectin-7. The median age